Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from Vectus Biosystems Limited ( (AU:VBS) ) is now available.
Vectus Biosystems Limited has applied to the ASX for quotation of 25,000 new fully paid ordinary shares, to be issued on 23 December 2025. The small equity issuance, arising from the exercise or conversion of existing options or convertible securities, marginally increases the company’s free float and may modestly enhance trading liquidity without materially altering its capital structure.
The most recent analyst rating on (AU:VBS) stock is a Hold with a A$0.10 price target. To see the full list of analyst forecasts on Vectus Biosystems Limited stock, see the AU:VBS Stock Forecast page.
More about Vectus Biosystems Limited
Vectus Biosystems Limited is an Australian-listed biotechnology company (ASX: VBS). The firm operates in the life sciences sector, focusing on the development and commercialisation of medical and biopharmaceutical technologies.
Average Trading Volume: 95,158
Technical Sentiment Signal: Sell
Current Market Cap: A$5.87M
For an in-depth examination of VBS stock, go to TipRanks’ Overview page.